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improvement with a clear increase in cardiac output and decrease
in PCWP. Levosimendan was associated with significantly
improved dyspnea and a trend towards improved fatigue. Inten-
sive care unit stay in levosimendan group is 1 day shorter than
that of the standard treatment group. This shows that the hos-
pitalization costs may be reduced by adopting levosimendan
treatment.
Evaluation of the role of multiple biomarkers in
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Background: The aim of the study was to evaluate the role of
multiple biomarkers in short term prognosis of heart failure
patients.
Methods: One hundred cases of heart failure diagnosed by Fra-
mingham’s criterion were taken up. Detailed history, clinical ex-
amination and echocardiographic analysis were done in each
patient. On the day of admission BNP, cTNT, cystatin C and NGAL
levels were estimated. Based on level of each biomarkers, the
patients were divided in two groups for prognostication purpose
for each biomarkers. BNP( > 300pg/ml vs < 300 pg/ml), cTNT ( >
0.03 ng/ml vs <0.03ng/ml and NGAL( > 140mg/l vs <140mg/l) Pa-
tients were followed up for ten days. Improvement or deteriora-
tion in symptoms and NYHA class were noted. Mortality if any
was also noted.
Results: It was observed that there is positive correlation between
clinical deterioration/ mortality and individual levels of BNP,
cTNT and cystatinC based on pre selected cut off value. Combi-
nation of BNP, cTNT and cystatin C all three levels above the cut
off value was associated with 62% of patients showing deteriora-
tion compared to 16% in all these below cut off. Similarly, patients
with combined BNP and cystatin C elevation showed 55% vs 23 %
and BNP and cTNT combined showed 60% vs 28% deterioration in
clinical symptoms.
Conclusions: Combination of BNP, cTNT and Cystatin C is better in
predicting short term outcome in patients of heart failure than
individual biomarkers.
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Background: There is growing evidence that anaemia is common
in CHF and may contribute to the high morbidity and mortality
associated with this condition. However, considerable disagree-
ment exists about the prevalence of anemia in CHF patients, with
prevalence rates varying from 9.9% to 55.6%.
Objective: To find the Prevalence of Anaemia in chronic heart
failure and Contribution of Iron deficiency and Renal dysfunction
as underlying cause.
Methods: We studied 200 patients. All the patients were NYHA
class III or IV, 82% being class IV. Haemoglobin concentration of 11
g/dl or less was selected as our cut-off for anaemia. This group
was further subdivided into microcytic, normocytic, and macro-
cytic anaemia. In each of these groups it was noted if any patients
had renal impairment (creatinine >1.5mg/dl) and whether ferritin
was low (<15mcg/l).
Results: Seventy of the 200 patients (35%) selected had a mean
haemoglobin concentration of < 11 g/dl. Of these 70 patients,
20(28.6%) were microcytic, 41(58.6%) were normocytic and
9(12.8%) were macrocytic. In microcytic group, ferritin was low in
12(17.1%) and renal impairment were in 5(7.1%) patients. In nor-
mocytic group, ferritin was low in 7(10%) and renal impairment
were in 23(32.8%) patients. Inmacrocytic group, ferritin was low in
2(2.8%) and renal impairment were in 4 (5.7%) patients. As a
whole, renal impairment was present in 32 patients (45.7%) and
low ferritin was present in 21(30%) patients. The prevalence of
anemia increased from 17.72 % in thosewith a serum creatinine of
< 1.5 mg/dl to 87.5% in those with a serum creatinine of >2.5 mg%.
Conclusion: Anemia is a common finding in patients hospitalized
with CHF and significant numbers of anaemic CHF patients have
some degree of renal insufficiency or iron deficiency.
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Background: The gain in life expectancy due to anthracycline
therapy might be countered by increased mortality due to car-
diotoxicity. The natural history of anthracycline induced cardio-
myopathy (AC-CMP) , remains poorly defined.
Objective: To study clinical profile of patients with AC-CMP and
response to heart failure (HF) therapy.
Methods: This is an analysis of prospectively collected data of
patients with a left ventricular ejection fraction (LVEF) 50 % due
to AC-CMP seen at a tertiary cancer centre in India .Patients with a
minimum follow up of 6 months, a baseline 2Decho,and at least
three 2Dechos after diagnosis of AC-CMP were included. De-
mographic details, comorbidities, cancer diagnosis and treatment
details including dose of anthracycline, treatment for CMP and
response to treatment (ACE inhibitors, beta blockers and or
digoxin) were recorded. Patients were considered responders and
nonresponders according to recovery in LVEF. Univariate and
multivariate analysis of effect of predictor variables on response
to treatment was done. Analyses were performed using PASW
software package (version 18).
Results: 55 patients newly diagnosed with AC-CMP were regis-
tered in 2010-2012. The median dose of doxorubicin was 300mg/
m2. Seven patients had received doxorubicin <¼ 180 mg/m2. Nine
patients (16.4%) presented with grade 4 cardiotoxicity and two
patients (3.6%) with grade 5. Median duration from last dose of
chemotherapy to development of AC-CMP was 5 months. The
median follow up duration was 15 months. 30 (54.5%) were re-
sponders. Age, co morbidities, mediastinal/left chest radiation,
doxorubicin dose, time to development of AC CMP did not affect
the response to treatment in univariate analysis. There was a
higher chance of non response in patients who received doxoru-
bicin more than 200mg/m2 (37%) and patients with grade 4
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cardiotoxicity (87%), however the difference was not statistically
significant.
Conclusions: AC CMP can occur at lower cumulative doses.
Doxorubicin dose, time to development of AC CMP and grade of
cardiotoxicity did not affect the response to treatment. Large
prospective studies to explore the role of biomarkers and genetic
polymorphism in early detection and prevention of AC CMP
respectively need to be conducted.
Takotsubo cardiomyopathy (TCM) versus dilated
cardiomyopathy (DCM)
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Aims: To study the clinical profile of Takotsubo cardiomyopathy&
DCMP.
Methods: The study was conducted on 60 patients in Deptt of
Medicine G.S.V.M. Medical college, in between January 2012 to
September 2013.
Inclusion criteria were: Modified Mayo Criteria.
 Signs & Symptoms of Heart failure
 New ECG abnormalities( ST- segment elevation or T-wave
inversion or modest elevation in cardiac troponin)
 Left ventricular ejection fraction < 45%
 Absence of obstructive coronary disease
Echo done in all cases
Results: There is a significant difference in the sex distribution
between the two types of cardiomyopathies ( p¼0.02), DCMP being
more common in males (68%) while TCM more common in fe-
males (90%).
None of the cases of TCM presented with pedal edema & pan-
systolic murmur while 66% cases of DCMP had pedal edema & all
of them had pansystolic murmur ( p < 0.001)
There is a significant association between psychological stress&
TCM (p<0.001)
There is a significant association between Alcohol & DCMP.
All TCM cases had a very good prognosis & all cases improved
significantly within 3 months
Conclusion: DCMP is more common in males(68%) while TCM is
more common in females (90%).
None of the cases of TCM presented with pedal edema & pan-
systolic murmur while cases of DCMP had pedal edema & all of
them had pansystolic murmur.
There is a significant association between psychological stress&
TCM.
There is a significant association between Alcohol & DCMP.
All TCM cases had a very good prognosis & all cases improved
significantly within 3 months with proper management and care.
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Background: Uremic cardiomyopathy is the most important
cause of death amongst end stage renal disease. The incidence
of Ischemic heart disease (IHD) in such patients is only 11%
worldwide. However, incidence of IHD is unknown in Eastern
Indian end stage renal disease patients with uremic
cardiomyopathy.
Methods: A total of 90 patients who underwent renal trans-
plantation at our institute were enrolled for the study. All un-
derwent Echocardiography as routine pre-transplant evaluation
protocol. Those with uremic cardiomyopathy underwent Dobut-
amine Stress Echocardiography (DSE) for assessment of the
presence of IHD. All such patients were also evaluated for pres-
ence or absence of standard CAD risk factors.
Results: 30 out of 90 patients (33%) were diagnosed to have Uremic
cardiomyopathy. 23 patients were male and 7 were female. 11%
were smokers, 10% hypertensives, 9% diabetics and 10% were
dyslipidemic. DSE was positive in only 5 patients (16.66%).
Conclusion: The incidence of IHD in end stage renal failure pa-
tients with Uremic Cardiomyopathy in Eastern India is higher
than the world literature.
Guideline recommended medication use among
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S. Virani
Baylor College of Medicine, Houston, Texas, USA
Background: Angiotensin converting enzyme inhibitors (ACE-I) or
angiotensin receptor blockers (ARB) and beta blockers (BB) are
class I indications in heart failure (HF) patients with an ejection
fraction (EF) <40%. Little is known about the use of these medi-
cations in outpatients with systolic HF in India.
Methods: PINNACLE® India is the first cardiovascular quality
improvement program in India to capture, report and improve
outpatient performance measure. Among patients with EF <40%
enrolled between January 2012 and June 2014from 11 outpatient
centers, we evaluated the use of ACE-I/ARB, BB or both on any
outpatient encounter.
Results: In 52880 patients with reported EF, 15940 (30%) had an EF
40%.The frequency of ACE-I/ARB; BB; and combined ACE-I/
ARB+BB use was documented in 5257 (33%); 5450 (34%); and 4647
(29%) of patients with EF40%, respectively. Women, patients >65
years and those receiving care in practices without electronic
medical records had lower documented medication use(Ta-
ble).The number of patients receiving recommended medications
increased after the first 3 months of reporting and subsequently
remained steady(data not shown).
Conclusions: Among patients with systolic HF enrolled in the
PINNACLE® India Registry, about 2/3rddid not have documen-
tation of receipt of guideline recommended medications. A
small improvement was observed in follow-up reporting. These
results indicate an opportunity to improve quality of care
concordant with treatment guidelines for patients with EF <40%
in India.
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